Literature DB >> 27771384

The new kidney allocation system does not equally advantage all very high cPRA candidates - A single center analysis.

Amy B Hahn1, Maryanne Mackey2, Don Constantino2, Ashar Ata3, Nikolaos Chandolias4, Reynold Lopez-Soler4, David J Conti4.   

Abstract

The new UNOS kidney allocation system awards very high points to candidates with cPRA 99% and 100%, and allows for national sharing for cPRA 100% candidates. We sought to determine the effect of this new kidney allocation system on candidates who are very highly sensitized (90-98% cPRA) but not eligible for very high points or national sharing by examining offers to these candidates for 5months pre-implementation and two consecutive 5month periods post-implementation and comparing them to cPRA⩾99% candidates. We found that the cPRA⩾99% candidates received significantly more offers and transplants after implementation, while offers and transplants to the 90-98% candidates decreased. A slight adjustment to the allocation system may be needed to provide more equitable distribution of kidneys to all high cPRA candidates.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Allocation; Antibody; Kidney; Renal; Transplant

Mesh:

Substances:

Year:  2016        PMID: 27771384     DOI: 10.1016/j.humimm.2016.10.010

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Authors:  Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall
Journal:  Am J Transplant       Date:  2018-12-15       Impact factor: 8.086

2.  The national landscape of deceased donor kidney transplantation for the highly sensitized: Transplant rates, waitlist mortality, and posttransplant survival under KAS.

Authors:  Kyle R Jackson; Karina Covarrubias; Courtenay M Holscher; Xun Luo; Jennifer Chen; Allan B Massie; Niraj Desai; Daniel C Brennan; Dorry L Segev; Jacqueline Garonzik-Wang
Journal:  Am J Transplant       Date:  2018-11-26       Impact factor: 8.086

3.  Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

Authors:  Christian Kjellman; Angela Q Maldonado; Kristoffer Sjöholm; Bonnie E Lonze; Robert A Montgomery; Anna Runström; Tomas Lorant; Niraj M Desai; Christophe Legendre; Torbjörn Lundgren; Bengt von Zur Mühlen; Ashley A Vo; Håkan Olsson; Stanley C Jordan
Journal:  Am J Transplant       Date:  2021-07-19       Impact factor: 9.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.